drugset / Trial / NCT02158273

Medication Development in Alcoholism: Investigating PPAR Agonists

NCT02158273

RandomizedParallel-groupTriple-blindOther

Summary

The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.

Timeline

Start
2014-05
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fenofibrate Small molecule 145 mg Oral

Indications